Hims & Hers Health, Inc. (HIMS)
| Market Cap | 12.42B |
| Revenue (ttm) | 1.78B |
| Net Income (ttm) | 164.40M |
| Shares Out | 223.83M |
| EPS (ttm) | 0.68 |
| PE Ratio | 81.37 |
| Forward PE | 67.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,386,722 |
| Open | 55.43 |
| Previous Close | 57.15 |
| Day's Range | 54.67 - 57.68 |
| 52-Week Range | 13.47 - 72.98 |
| Beta | 2.10 |
| Analysts | Hold |
| Price Target | 38.00 (-31.51%) |
| Earnings Date | Aug 4, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price forecast is $38.0, which is a decrease of -31.51% from the latest price.
News
Hims & Hers: An Excellent Subscription Business
Hims & Hers offers a high-growth, recurring subscription telehealth business with strong user and revenue growth, expanding into multiple health segments. It is the market leader in telehealth easily ...
Hims & Hers: The ZAVA Acquisition Catapults Growth In Europe's Weight-Loss Market
Hims & Hers Health's acquisition of ZAVA fast-tracks its entry into Europe's weight-loss market, expanding its subscriber base by 54%. The deal is attractively priced, non-dilutive, and leverages ZAVA...
Hims & Hers says its weight-loss business can grow as US market changes
Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some analysts see a need for the online website to adjust to changing competition in...
Hims & Hers ZAVA Acquisition Deal Expands Its Market Opportunity By $52 Billion: Analyst
Hims & Hers Health, Inc. HIMS on Tuesday agreed to acquire ZAVA, a European digital health platform. The deal terms were not disclosed.
Hims & Hers stock price jumps: Telehealth company acquires Zava, picking up over a million Europe customers
American telehealth company Hims & Hers Health announced on Tuesday that it will be acquiring Zava, a leading European digital health company in an all cash acquisition set to close in the second half...
Top Stock Movers Now: Dollar General, Hims & Hers, Bumble, and More
U.S. equities rose at midday as the markets continued to wait for more information about possible U.S. trade deals. The Dow Jones Industrial Average, S&P 500, and Nasdaq were slightly higher.
Hims & Hers Expands in Europe With Acquisition of ZAVA
Hims & Hers Health (HIMS) shares rose Tuesday after the health and wellness site announced it was expanding its reach into Europe by buying London-based digital health platform ZAVA. The price of the ...
Hims expands into Europe with Zava acquisition
CNBC's Brandon Gomez reports on the latest news regarding Hims.
Hims & Hers Expands into Europe, Seeking Growth as Weight Loss Business Shifts
Hims agreed to buy private European telehealth firm Zava, which operates in the U.K., Germany, France, and Ireland.
Hims to acquire UK-based startup Zava as it expands international presence
Telehealth platform Hims & Hers said on Tuesday it will acquire London-based startup Zava for an undisclosed amount, allowing it to launch its offerings in Germany, France and Ireland and reach more i...
Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced a significant step in its global expansion through its agreement to acq...
Hims & Hers to acquire European telehealth platform in global expansion
Hims & Hers Health announced Tuesday it will acquire European telehealth platform Zava. The deal will expand Hims' services to Ireland, France and Germany and will grow its active customer base by rou...
Hims & Hers: Still Huge Potential Ahead
Hims & Hers Health, Inc is a telehealth platform offering tailored health and wellness services, showing significant stock volatility recently. HIMS experienced a dramatic rise from $24.11 to $68.75 i...
Hims & Hers: Peptide And Short Squeeze Are Coming!
Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1, positioning itself as a leader in the biohacking and longevity markets. The company's strategic moves...
What's Happening With HIMS Stock?
Hims & Hers Health (NYSE: HIMS), a telehealth platform, experienced an 8% increase in its stock on Friday, May 30th, following the announcement of a 4% reduction in its workforce. This move comes as t...
Hims to cut 4% of workforce amid ban on weight-loss drug copies
Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy.
Hims & Hers Health Stock: After Doubling, It May Be Too Late To Buy
Hims & Hers Health shows strong growth in subscribers, revenue, and profitability, driven by expanding offerings and strategic partnerships, especially in weight loss and dermatology. HIMS posted stel...
Hims & Hers Health: New Guidance Creates Huge Risk For Shorts
Hims & Hers Health continues to fire on all cylinders as a business, growing at extraordinary rates while also improving its margins. Today, I will offer a unique and simplified view of the business b...
Avoid These Dividend Disasters Before It's Too Late
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Hims & Hers Introduces 6-Month Wegovy® New Customer Offer
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obes...
Hims & Hers: After A Bout Of Uncertainty, Upside Remains
Hims & Hers continues to deliver strong subscriber and revenue growth, with Q1 2025 revenue up 111% year-over-year and operating leverage improving. The business model's shift to a subscription platfo...
Hims & Hers: Growth, Strategic Partnerships, And Operational Leverage (Upgrade)
Hims & Hers Health's rapid revenue and subscriber growth, plus improving cash generation, highlight strong business momentum and brand strength. Gross margins have declined due to lower-margin obesity...
Hims & Hers stock price nears crucial level: is it a buy or sell?
Hims & Hers stock price has surged and is nearing its all-time high as investors bet that its strong momentum will continue in the coming years. HIMS shares surged by almost 16% on Tuesday, reaching i...
50% Upside For HIMS Stock?
Hims & Hers (NASDAQ:HIMS), a telehealth platform with a market capitalization of $14 billion, has seen its stock rise by 150% this year. The stock now trades at over 10x trailing revenues, raising que...
Hims & Hers Health Stock: A Rare High-Growth Value Play In Plain Sight
Rarely I see high-growth, value plays in the market. I think Hims & Hers Health is such a rare case: a world-class, high-growth company still being valued as a risky startup. A DCF model based on 2030...